Better Biopharma
“How can biopharma improve?” This question is the guiding ethos of the Better Biopharma podcast. Through conversations with experts across the biopharma landscape, host Tyler Menichiello explores the work being done to make better medicines and optimize manufacturing. Each episode is a dive into the guest's methods, their curiosity, and their determination. By shining a light on the visionaries pushing the industry forward, Better Biopharma aims to inform and inspire their peers to continue doing the same.
Better Biopharma
Engineering Bacterial Vector-Based Immunotherapies With OS Therapies’ Paul Romness and Robert Petit, Ph.D.
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
In this episode of “Better Biopharma,” host Tyler Menichiello is joined by OS Therapies’ CEO, Paul Romness, and chief medical and scientific officer, Robert Petit, Ph.D. The three discuss the development and manufacturing of the company’s lead asset, OST-HER2, a Listeria-based immunotherapy for osteosarcoma. They also explain the unique CMC challenges around developing a safe bacterial vector.
Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/
Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/
Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions
Tell us how we can improve. Take our 60-second survey: https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header